https://scholars.lib.ntu.edu.tw/handle/123456789/593506
標題: | PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients | 作者: | Lee, Sze-Hwei CHIEN-CHIN LIN Wei, Chao-Hong Chang, Ko-Ping CHANG-TSU YUAN CHENG-HONG TSAI Liu, Jia-Hao HSIN-AN HOU Tang, Jih-Lu WEN-CHIEN CHOU HWEI-FANG TIEN |
關鍵字: | JAK2; PD-L1; SP142; checkpoint; megakaryocyte; primary myelofibrosis | 公開日期: | 一月-2022 | 出版社: | WILEY | 卷: | 8 | 期: | 1 | 起(迄)頁: | 78 | 來源出版物: | The journal of pathology. Clinical research | 摘要: | Myeloproliferative neoplasms (MPNs) are characterized by upregulation of proinflammatory cytokines and immune dysregulation, which provide a reasonable basis for immunotherapy in patients. Megakaryocytes are crucial in the pathogenesis of primary myelofibrosis (PMF), the most clinically aggressive subtype of MPN. In this study, we aimed to explore PD-L1 (programmed death-ligand 1) expression in megakaryocytes and its clinical implications in PMF. We analyzed PD-L1 expression on megakaryocytes in PMF patients by immunohistochemistry and correlated the results with clinicopathological features and molecular aberrations. We employed a two-tier grading system considering both the proportion of cells positively stained and the intensity of staining. Among the 85 PMF patients, 41 (48%) showed positive PD-L1 expression on megakaryocytes with the immune-reactive score ranging from 1 to 12. PD-L1 expression correlated closely with higher white blood cell count (p = 0.045), overt myelofibrosis (p = 0.010), JAK2V617F mutation (p = 0.011), and high-molecular risk mutations (p = 0.045), leading to less favorable overall survival in these patients (hazard ratio 0.341, 95% CI 0.135-0.863, p = 0.023). Our study provides unique insights into the interaction between immunologic and molecular phenotypes in PMF patients. Future work to explore the translational potential of PD-L1 in the clinical setting is needed. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/593506 | ISSN: | 2056-4538 | DOI: | 10.1002/cjp2.240 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。